Revolution Medicines Financials - Benzinga

Revolution Medicines Inc

RVMDNASDAQ

Trade with Public

Trade with Public

$204.97

5.112.56%

近くで: Sep 25, 5:00 PM EST

$207.01

2.041%

時間外: Sep 25, 6:35 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Revolution Medicines Financials

Revolution Medicines (RVMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the analyst consensus estimate of $(1.98) by 54.55 percent. This is a 133.59 percent decrease over losses of $(1.31) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Revolution Medicines Sees FY26 GAAP Operating Expenses $1.7B-$1.8B

Benzinga Newsdesk

PRO
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.82) by 25.82 percent. This is a 102.65 percent decrease over losses of $(1.13) per

Benzinga Newsdesk

Revolution Medicines: Q4 Earnings Insights

Benzinga Insights

PRO
Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.58) by 17.87 percent. This is a 66.07 percent decrease over losses of $(1.12) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved